Laboratorios Farmaceuticos Rovi, S.A.

MSE:ROVI.MC

65.75 (EUR) • At close November 7, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) EUR.

20232022202120202019201820172016201520142013201220112010200920082007200620052004
Revenue 829.509817.698648.677419.961381.313303.203275.649265.166246.009238.047217.587201.923184.706158.645115.157127.544100.7178.6297,846,545.2047,051.474
Cost of Revenue 337.224298.085263.855178.652166.606128.612108.135112.02497.07594.57884.89575.51369.43962.82150.32240.25532.92825.99207,642.001
Gross Profit 492.285519.613384.822241.309214.707174.591167.514153.142148.934143.469132.692126.41115.26795.82464.83587.28967.78252.6377,846,545.204-590.527
Gross Profit Ratio 0.5930.6350.5930.5750.5630.5760.6080.5780.6050.6030.610.6260.6240.6040.5630.6840.6730.6691-0.084
Reseach & Development Expenses 24.92323.86927.44523.80129.30432.37621.0330000000000000
General & Administrative Expenses 16.22312.78200000000000000002,034,437.5671,779.865
Selling & Marketing Expenses 21.75419.99312.71311.40919.52917.35417.46816.48820.95816.13317.23318.54000002,542,543.33900
SG&A 37.97719.99312.71311.40919.52917.35417.46816.48820.95816.13317.23318.54000002,542,543.3392,034,437.5671,779.865
Other Expenses -5.764243.77190.622152.471151.994139.779131.037108.354106.13499.64489.98786.19396.28269.82150.93633.4952.3961.279769,220.7511,056.122
Operating Expenses 272.031263.763203.335163.88171.523157.133148.505124.842127.092115.777107.22104.73396.28269.82150.93633.49551.7450.4232,420,378.1382,146.805
Operating Income 220.254255.848181.57474.68242.84317.45819.00928.321.84227.69225.47221.67718.98526.00313.89928.3218.4383.493291,589.599625.793
Operating Income Ratio 0.2660.3130.280.1780.1120.0580.0690.1070.0890.1160.1170.1070.1030.1640.1210.2220.1830.0440.0370.089
Total Other Income Expenses Net 0.1542.1191.054-2.101-0.963-0.778-1.487-0.418-0.944-2.058-1.221-0.839-0.057-0.08210.408-0.1621.420.751769,220.7511,034.067
Income Before Tax 220.408257.967182.62872.58141.8816.6817.52227.88220.89825.63424.25120.83818.92825.92124.30728.15819.8584.2441,060,810.351,659.861
Income Before Tax Ratio 0.2660.3150.2820.1730.110.0550.0640.1050.0850.1080.1110.1030.1020.1630.2110.2210.1970.0540.1350.235
Income Tax Expense 50.10958.30229.55111.5242.607-1.2150.2811.7931.0891.5181.2291.3240.8011.3391.1684.6164.9-0.492-148,680.00670.762
Net Income 170.335199.669153.07761.05739.27317.89517.24126.08919.80924.11623.02219.51418.12724.58223.13923.54214.9585.061912,130.3451,582.665
Net Income Ratio 0.2050.2440.2360.1450.1030.0590.0630.0980.0810.1010.1060.0970.0980.1550.2010.1850.1490.0640.1160.224
EPS 3.293.732.761.10.710.350.350.530.40.480.460.390.360.490.410.410.30.0918,24231.65
EPS Diluted 3.293.732.761.10.710.350.350.530.40.480.460.390.360.490.410.410.30.0918,24231.65
EBITDA 245.597279.626202.68796.76860.92629.45930.01439.8232.65437.12132.72227.63625.92531.07726.75231.23216.7862.564421,539.9391,726.089
EBITDA Ratio 0.2960.3420.3120.230.160.0970.1090.150.1330.1560.150.1370.140.1960.2320.2450.1670.0330.0540.245